GBT

Global Blood
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.09
-0.95
-1.83%
After Hours: 51.09 0 0.00% 17:56 03/31 EDT
OPEN
51.53
PREV CLOSE
52.04
HIGH
52.49
LOW
49.03
VOLUME
747.99K
TURNOVER
--
52 WEEK HIGH
87.54
52 WEEK LOW
39.95
MARKET CAP
3.11B
P/E (TTM)
-11.2347
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GBT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GBT stock price target is 99.63 with a high estimate of 150.00 and a low estimate of 60.00.

EPS

GBT News

More
  • Why Is Global Blood (GBT) Down 15% Since Last Earnings Report?
  • Zacks · 4d ago
  • Edited Transcript of GBT earnings conference call or presentation 26-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/18 15:52
  • Director Willie Brown Just Bought Shares In Global Blood Therapeutics, Inc. (NASDAQ:GBT)
  • Simply Wall St. · 03/18 11:40
  • GBT Takes Steps to Support Public Health Efforts to Address COVID-19 Pandemic
  • GlobeNewswire · 03/17 13:00

Industry

Biotechnology & Medical Research
-0.26%
Pharmaceuticals & Medical Research
-0.17%

Hot Stocks

Symbol
Price
%Change

About GBT

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
More

Webull offers kinds of Global Blood Therapeutics Inc stock information, including NASDAQ:GBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GBT stock news, and many more online research tools to help you make informed decisions.